+1,119.4%
NBIS vs GSK
+36.6%
+1,082.8%
-58.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +7.7% | -2.7% | +10.4% | +6.6% |
| 7D | +22.2% | -4.2% | +26.4% | +20.3% |
| 30D | +29.7% | -7.5% | +37.3% | +26.9% |
| 3M | +11.9% | -3.3% | +15.2% | +11.2% |
| 6M | +173.0% | -9.3% | +182.3% | +169.0% |
| YTD | +191.4% | +1.6% | +189.8% | +196.4% |
| 1Y | +280.7% | +25.5% | +255.2% | +302.5% |
| All | +1,119.4% | +36.6% | +1,082.8% | +1,701.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling